Last reviewed · How we verify

NCT06075732

ACTIVATE in Public Housing

Completed NA Last updated 17 February 2025
What this trial tests

NA trial testing Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination in Pneumonia in 400 participants. Completed in 2 December 2024.

Timeline
1 July 2024
Primary endpoint
30 November 2024
2 December 2024

Quick facts

Lead sponsorCharles Drew University of Medicine and Science
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment400
Start date1 July 2024
Primary completion30 November 2024
Estimated completion2 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Charles Drew University of Medicine and Science

Who can join

18 and older, any sex, with Pneumonia or Influenza. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase influenza, meningitis, pneumonia, VZV, and COVID-19 vaccine rates among under-resourced African American and Latino public housing residents in South Los Angeles.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pneumonia

Currently open trials in the same condition.

Other Charles Drew University of Medicine and Science trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06075732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing